Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
Johnson and Johnson
Mallinckrodt
Medtronic
Express Scripts

Last Updated: May 28, 2022

Acelrx Pharms Company Profile


✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for ACELRX PHARMS, and what generic alternatives to ACELRX PHARMS drugs are available?

ACELRX PHARMS has one approved drug.

There are eighteen US patents protecting ACELRX PHARMS drugs.

There are eighty-three patent family members on ACELRX PHARMS drugs in nineteen countries and six supplementary protection certificates in five countries.

Summary for Acelrx Pharms
International Patents:83
US Patents:18
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Acelrx Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Acelrx Pharms DSUVIA sufentanil citrate TABLET;SUBLINGUAL 209128-001 Nov 2, 2018 RX Yes Yes 8,574,189 See Plans and Pricing Y See Plans and Pricing
Acelrx Pharms DSUVIA sufentanil citrate TABLET;SUBLINGUAL 209128-001 Nov 2, 2018 RX Yes Yes 8,945,592 See Plans and Pricing Y See Plans and Pricing
Acelrx Pharms DSUVIA sufentanil citrate TABLET;SUBLINGUAL 209128-001 Nov 2, 2018 RX Yes Yes 8,865,211 See Plans and Pricing See Plans and Pricing
Acelrx Pharms DSUVIA sufentanil citrate TABLET;SUBLINGUAL 209128-001 Nov 2, 2018 RX Yes Yes 9,744,129 See Plans and Pricing Y See Plans and Pricing
Acelrx Pharms DSUVIA sufentanil citrate TABLET;SUBLINGUAL 209128-001 Nov 2, 2018 RX Yes Yes 8,535,714 See Plans and Pricing Y See Plans and Pricing
Acelrx Pharms DSUVIA sufentanil citrate TABLET;SUBLINGUAL 209128-001 Nov 2, 2018 RX Yes Yes 8,252,329 See Plans and Pricing Y See Plans and Pricing
Acelrx Pharms DSUVIA sufentanil citrate TABLET;SUBLINGUAL 209128-001 Nov 2, 2018 RX Yes Yes 10,507,180 See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for Acelrx Pharms Drugs

Country Patent Number Estimated Expiration
South Korea 20090096747 See Plans and Pricing
World Intellectual Property Organization (WIPO) 2008085765 See Plans and Pricing
World Intellectual Property Organization (WIPO) 2010059504 See Plans and Pricing
World Intellectual Property Organization (WIPO) 2010107761 See Plans and Pricing
Japan 2012509325 See Plans and Pricing
China 101394863 See Plans and Pricing
South Korea 20080084858 See Plans and Pricing
>Country >Patent Number >Estimated Expiration

Supplementary Protection Certificates for Acelrx Pharms Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2114383 SPC/GB16/004 United Kingdom See Plans and Pricing PRODUCT NAME: SUFENTANIL; REGISTERED: UK EU/1/15/1042 20150922
2114383 CA 2016 00007 Denmark See Plans and Pricing PRODUCT NAME: SUFENTANIL, HERUNDER SUFENTANIL SOM CITRAT; REG. NO/DATE: EU/1/15/1042/001-006 20150922
2114383 122016000023 Germany See Plans and Pricing PRODUCT NAME: SUFENTANIL, WAHLWEISE IN FORM VON SUFENTANILCITRAT; REGISTRATION NO/DATE: EU/1/15/1042 20150918
2114383 CR 2016 00007 Denmark See Plans and Pricing PRODUCT NAME: SUFENTANIL; REG. NO/DATE: EU/1/15/1042/001-006 20150922
2114383 300797 Netherlands See Plans and Pricing PRODUCT NAME: SUFENTANIL, DESGEWENST IN DE VORM VAN SUFENTANILCITRAAT; REGISTRATION NO/DATE: EU/1/15/1042 20150922
2114383 16C0010 France See Plans and Pricing PRODUCT NAME: SUFENTANIL; REGISTRATION NO/DATE: EU/1/15/1042 20150918
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
Dow
McKinsey
Medtronic
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.